Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 116.5% in November

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 214,800 shares, a growth of 116.5% from the November 15th total of 99,200 shares. Based on an average trading volume of 249,100 shares, the days-to-cover ratio is currently 0.9 days.

Enlivex Therapeutics Stock Performance

ENLV opened at $1.20 on Friday. The stock has a market cap of $25.69 million, a price-to-earnings ratio of -1.22 and a beta of 1.01. The stock’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.34. Enlivex Therapeutics has a one year low of $0.81 and a one year high of $4.59.

Institutional Trading of Enlivex Therapeutics

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of Enlivex Therapeutics in the second quarter valued at approximately $35,000. Sigma Investment Counselors Inc. purchased a new stake in shares of Enlivex Therapeutics in the third quarter valued at approximately $50,000. Finally, Armistice Capital LLC purchased a new stake in shares of Enlivex Therapeutics in the second quarter valued at approximately $2,415,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Analysts Set New Price Targets

ENLV has been the topic of several analyst reports. EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. D. Boral Capital reaffirmed a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Enlivex Therapeutics in a research note on Friday, September 27th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.